+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Alzheimer's Disease Treatment Global Market Report 2020-30: COVID-19 Growth and Change

  • ID: 5214041
  • Report
  • December 2020
  • Region: Global
  • The Business Research Company

FEATURED COMPANIES

  • AB Science
  • Allergan
  • Bayer AG
  • Eli Lilly and Company
  • H. Lundbeck A/S Biogen
  • Novartis AG
  • MORE
Alzheimer’s Disease Treatment Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global alzheimer’s disease treatment market.

This report focuses on alzheimer’s disease treatment market which is experiencing strong growth. The report gives a guide to the alzheimer’s disease treatment market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Description:

Where is the largest and fastest growing market for the alzheimer’s disease treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Alzheimer’s Disease Treatment market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider alzheimer’s disease treatment market, and compares it with other markets.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The alzheimer’s disease treatment market section of the report gives context. It compares the alzheimer’s disease treatment market with other segments of the alzheimer’s disease treatment market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, alzheimer’s disease treatment indicators comparison.
Scope

Markets Covered:

1) By Drug Class: Cholinergic; Memantine; Combined Drug; AChE inhibitors; Immunoglobulins
2) By Drug Type: Cholinesterase Inhibitors; NMDA Receptor Antagonists

Companies Mentioned: Allergan; Eisai Co. Ltd.; Novartis AG; Pfizer Inc.; Merz Pharma

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

This report will be delivered within 1-3 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AB Science
  • Allergan
  • Bayer AG
  • Eli Lilly and Company
  • H. Lundbeck A/S Biogen
  • Novartis AG
  • MORE
1. Executive Summary

2. Alzheimer’s Disease Treatment Market Characteristics

3. Alzheimer’s Disease Treatment Market Size And Growth
3.1. Global Alzheimer’s Disease Treatment Historic Market, 2015 - 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Alzheimer’s Disease Treatment Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market

4. Alzheimer’s Disease Treatment Market Segmentation
4.1. Global Alzheimer’s Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Cholinergic
  • Memantine
  • Combined Drug
  • AChE inhibitors
  • Immunoglobulins
4.2. Global Alzheimer’s Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Cholinesterase Inhibitors
  • NMDA Receptor Antagonists
5. Alzheimer’s Disease Treatment Market Regional And Country Analysis
5.1. Global Alzheimer’s Disease Treatment Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5.2. Global Alzheimer’s Disease Treatment Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

6. Asia-Pacific Alzheimer’s Disease Treatment Market
6.1. Asia-Pacific Alzheimer’s Disease Treatment Market Overview
6.2. Asia-Pacific Alzheimer’s Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

7. China Alzheimer’s Disease Treatment Market
7.1. China Alzheimer’s Disease Treatment Market Overview
7.2. China Alzheimer’s Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion

8. India Alzheimer’s Disease Treatment Market
8.1. India Alzheimer’s Disease Treatment Market Overview
8.2. India Alzheimer’s Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

9. Japan Alzheimer’s Disease Treatment Market
9.1. Japan Alzheimer’s Disease Treatment Market Overview
9.2. Japan Alzheimer’s Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

10. Australia Alzheimer’s Disease Treatment Market
10.1. Australia Alzheimer’s Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

11. Indonesia Alzheimer’s Disease Treatment Market
11.1. Indonesia Alzheimer’s Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

12. South Korea Alzheimer’s Disease Treatment Market
12.1. South Korea Alzheimer’s Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

13. Western Europe Alzheimer’s Disease Treatment Market
13.1. Western Europe Alzheimer’s Disease Treatment Market Overview
13.2. Western Europe Alzheimer’s Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

14. UK Alzheimer’s Disease Treatment Market
14.1. UK Alzheimer’s Disease Treatment Market Overview
14.2. UK Alzheimer’s Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

15. Germany Alzheimer’s Disease Treatment Market
15.1. Germany Alzheimer’s Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

16. France Alzheimer’s Disease Treatment Market
16.3. France Alzheimer’s Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

17. Eastern Europe Alzheimer’s Disease Treatment Market
17.1. Eastern Europe Alzheimer’s Disease Treatment Market Overview
17.2. Eastern Europe Alzheimer’s Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

18. Russia Alzheimer’s Disease Treatment Market
18.1. Russia Alzheimer’s Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

19. North America Alzheimer’s Disease Treatment Market
19.1. North America Alzheimer’s Disease Treatment Market Overview
19.2. North America Alzheimer’s Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

20. USA Alzheimer’s Disease Treatment Market
20.1. USA Alzheimer’s Disease Treatment Market Overview
20.2. USA Alzheimer’s Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

21. South America Alzheimer’s Disease Treatment Market
21.1. South America Alzheimer’s Disease Treatment Market Overview
21.2. South America Alzheimer’s Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

22. Brazil Alzheimer’s Disease Treatment Market
22.1. Brazil Alzheimer’s Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

23. Middle East Alzheimer’s Disease Treatment Market
23.1. Middle East Alzheimer’s Disease Treatment Market Overview
23.2. Middle East Alzheimer’s Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

24. Africa Alzheimer’s Disease Treatment Market
24.1. Africa Alzheimer’s Disease Treatment Market Overview
24.2. Africa Alzheimer’s Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

25. Alzheimer’s Disease Treatment Market Competitive Landscape And Company Profiles
25.1. Alzheimer’s Disease Treatment Market Competitive Landscape
25.2. Alzheimer’s Disease Treatment Market Company Profiles
25.2.1. Allergan
25.2.1.1. Overview
25.2.1.2. Products and Services
25.2.1.3. Strategy
25.2.1.4. Financial Performance
25.2.2. Eisai Co. Ltd.
25.2.2.1. Overview
25.2.2.2. Products and Services
25.2.2.3. Strategy
25.2.2.4. Financial Performance
25.2.3. Novartis AG
25.2.3.1. Overview
25.2.3.2. Products and Services
25.2.3.3. Strategy
25.2.3.4. Financial Performance
25.2.4. Pfizer Inc.
25.2.4.1. Overview
25.2.4.2. Products and Services
25.2.4.3. Strategy
25.2.4.4. Financial Performance
25.2.5. Merz Pharma
25.2.5.1. Overview
25.2.5.2. Products and Services
25.2.5.3. Strategy
25.2.5.4. Financial Performance

26. Key Mergers And Acquisitions In The Alzheimer’s Disease Treatment Market

27. Alzheimer’s Disease Treatment Market Trends And Strategies

28. Alzheimer’s Disease Treatment Market Future Outlook and Potential Analysis

29. Appendix
29.1. Abbreviations
29.2. Currencies
29.3. Research Inquiries
29.4. About the Publisher
29.5. Copyright And Disclaimer
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AB Science
  • Allergan
  • Bayer AG
  • Eli Lilly and Company
  • H. Lundbeck A/S Biogen
  • Novartis AG
  • MORE
Major players in the Alzheimer’s disease treatment market are Allergan, Eisai Co. Ltd., Novartis AG, Pfizer Inc., Merz Pharma, H. Lundbeck A/S Biogen, AstraZeneca, and F. Hoffmann-La Roche Ltd.

The global Alzheimer’s disease treatment market is expected to decline from $3.46 billion in 2019 to $3.42 billion in 2020 at a compound annual growth rate (CAGR) of -1.26%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $4.96 billion in 2023 at a CAGR of 13.21%.

The global Alzheimer’s disease treatment market consists of sales of drugs used to treat Alzheimer’s disease. Alzheimer's disease is a progressive neurological disorder causing degeneration of brain cells, resulting in dementia (a condition that causes a decline in thinking, behavioral and social skills). The progression of this disease causes severe memory impairment and the person may lose the ability to carry out everyday tasks.

North America was the largest region in Alzheimer’s disease treatment market in 2019. Asia-Pacific is expected to be the fastest-growing region in the forecast period.

In January 2020, Biogen Inc., an American multinational biotechnology company, acquired Pfizer Inc. for an upfront payment of $75 million with up to $635 million in potential additional development and commercialization milestone payments. Through this acquisition, Biogen plans to develop the Phase 1 asset for the treatment of Sundowning in Alzheimer’s disease (AD) and Irregular Sleep Wake Rhythm Disorder (ISWRD) in Parkinson’s disease (PD). Pfizer Inc. is an American multinational pharmaceutical corporation engaged in the discovery, development and manufacture of healthcare products including medicines and vaccines.

The Alzheimer’s disease treatment market covered in this report is segmented by drug class into cholinergic; memantine; combined drug; AChE inhibitors; immunoglobulins and by drug type into cholinesterase inhibitors; NMDA receptor antagonists.

Lack of techniques for diagnosing Alzheimer’s disease (AD) is expected to limit the growth of the global Alzheimer’s disease treatment market. There is no definitive blood test, brain scan, or physical exam to diagnose AD, and so many conditions can produce symptoms like dementia, which is the primary clinical symptom of AD, making the diagnosis complicated. The lack of a single test for diagnosis, specialists such as neurologists, neuropsychologists, geriatricians and geriatric psychiatrists use a variety of approaches for diagnosis to confirm dementia, but it is still difficult to find the cause resulting in late diagnosis. Lack of proper and quick diagnosis for AD hampers the market growth as it leads to a reduced number of diagnosed cases and thereby reduces the consumption of AD drugs.

Increasing R&D investments and collaborations due to the emerging technologies for the treatment is a key trend in Alzheimer’s disease (AD) treatment market. The Alzheimer's Association is assisting with funds to researchers in search of innovative therapeutic approaches and seeks more government funding for Alzheimer's studies. Technologies such as β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors and anti-amyloid inhibitors are emerging in the AD market. For instance, Comentis and Astellas collaborated and entered the BACE inhibitor field on their peptidomimetic series. Manufacturing companies such as AC Immune, Adamas Pharmaceuticals, INmune Bio, Intra-Cellular Therapies, vTv Therapeutics are more focused on R&D investments with their research molecules in the clinical trials to achieve a breakthrough for the treatment of AD.

The increasing cases of Alzheimer's is a major factor contributing to the growth of the Alzheimer's treatment market. Alzheimer's is the most common type of dementia. The USA Alzheimer's Association expects that all the states in the US are projected to face a rise of at least 14% in the number of Alzheimer’s people between 2017 and 2025 due to the increase in the geriatric population. At the global level, the estimated new cases of Alzheimer’s were 454,000 in 2010 and the number is expected to grow by 35% to 615,000 by 2030, and by 110% to 959,000 by 2050. Therefore, the increasing prevalence of Alzheimer’s disease is expected to drive the growth of the global Alzheimer’s disease treatment market.
Note: Product cover images may vary from those shown
  • Allergan
  • Eisai Co. Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Merz Pharma
  • H. Lundbeck A/S Biogen
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Company
  • Teva Pharmaceutical Industries Ltd.
  • ONO PHARMACEUTICAL CO. LTD.
  • VTV Therapeutics
  • TauRx
  • AC Immune
  • AB Science
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Takeda Pharmaceutical Company Limited.
  • Bayer AG
  • Amgen
  • UCB
  • Forest Laboratories
  • Merck Sharp & Dohme Corp.
  • Biogen
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll